Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
Hao‐Wei Wang(Fu Jen Catholic University), Tao Jiang(Tongji University), Xuefei Li(Harbin Medical University), Fangfang Liu(University of Washington), Chao Zhao(Tongji University), Xiaoxia Chen(Guangdong Academy of Medical Sciences), Caicun Zhou(Tongji University), Qian Chu(Tongji Hospital), Jie Hu(Fudan University)
Cited by 36
Related Papers
Notch signaling pathway: architecture, disease, and therapeutics
|Signal Transduction and Targeted Therapy|2022|1k
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422